Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Revolution_Medicines' daraxonrasib...
Tech medical breakthrough

Revolution_Medicines' daraxonrasib extends pancreatic cancer survival

Analysis based on 74 articles · First reported May 29, 2026 · Last updated Jun 04, 2026

Sentiment
80
Attention
7
Articles
74
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The breakthrough in pancreatic cancer treatment with daraxonrasib is expected to significantly boost the stock of Revolution Medicines, the drug's developer. The expedited review and expanded access granted by the United States — Food and Drug Administration signal a rapid path to market, potentially increasing revenue and market share for Revolution Medicines in the oncology sector.

pharmaceuticals biotechnology healthcare
Event Summary

Researchers have reported a significant breakthrough in treating advanced pancreatic cancer with an experimental pill called daraxonrasib, developed by Revolution Medicines. The daily pill nearly doubled the median survival time for patients whose metastatic cancer had stopped responding to prior chemotherapy, extending it to 13.2 months compared to 6.7 months for chemotherapy recipients. The drug targets KRAS mutations, which fuel tumor growth in over 90% of pancreatic cancer cases, a target previously considered 'undruggable'. The findings were presented at the American Society of Clinical Oncology meeting and published in the The New England Journal of Medicine. The United States — Food and Drug Administration is expediting its review and has allowed expanded access to daraxonrasib. Key researchers like Zev Wainberg and Brian Wolpin highlighted the drug's potential to become a new standard of care, with fewer severe side effects than traditional chemotherapy. Former U.S. Senator Ben Sasse also publicly shared his positive experience with the drug, increasing public awareness and demand.

Key Actions
100 Revolution Medicines funded study
100 Daraxonrasib doubled survival time Pancreatic cancer
90 Brian Wolpin led trial
90 Revolution Medicines applied to license drug United States — Food and Drug Administration
80 United States — Food and Drug Administration expedite review
80 Daraxonrasib caused fewer side-effects
80 Revolution Medicines released press
80 Jennifer L. Knox reviewed study
75 Brian Wolpin presented findings
75 Daniel Renouf expects trials to open
70 Revolution Medicines funded trial Daraxonrasib
70 Eileen O Reilly authored paper
70 Jennifer L. Knox presented assessment American Society of Clinical Oncology
60 Ben Sasse described experience
50 American Society of Clinical Oncology presented trial results Daraxonrasib
Entities Involved
oth
Daraxonrasib
Daraxonrasib is a new drug that has shown unprecedented success in treating advanced pancreatic cancer, potentially doubling survival time and offering a new treatment option for patients.
Importance 100 Sentiment 90
stock
Revolution Medicines
Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.
Importance 95 Sentiment 90
oth
Pancreatic cancer
The new drug Daraxonrasib offers a significant breakthrough in treating Pancreatic cancer, a disease with a high mortality rate and limited treatment options.
Importance 90 Sentiment 70
per
Jennifer L. Knox
Jennifer L. Knox>>>, a medical oncologist and head of pancreatic cancer at Princess Margaret Cancer Centre, independently reviewed the daraxonrasib study and is spearheading efforts to bring clinical trials to Canada>>>. Her advocacy is crucial for patient access to the experimental drug.
Importance 90 Sentiment 75
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.
Importance 80 Sentiment 70
oth
KRAS
The KRAS gene mutation is targeted by Daraxonrasib, which is found in over 90% of Pancreatic cancer tumors and drives their growth.
Importance 80 Sentiment 80
cnt
Canada
Canada>>> is a primary focus of this event, with oncologists like Jennifer L. Knox>>> and Daniel Renouf>>> working to open clinical trials for daraxonrasib to benefit Canadian pancreatic cancer patients.
Importance 80 Sentiment 70
per
Zev Wainberg
Zev Wainberg, from the University of California, Los Angeles, helped lead the study on daraxonrasib and provided key insights into its effectiveness and significance.
Importance 75 Sentiment 70
per
Brian Wolpin
Brian Wolpin, from the Dana–Farber Cancer Institute, presented the findings of the daraxonrasib study and advocated for its adoption as a new standard of care.
Importance 75 Sentiment 70
per
Daniel Renouf
Daniel Renouf>>>, executive medical director for BC Cancer in Vancouver, also attended the meeting in Chicago and expects clinical trials for daraxonrasib to open soon in Vancouver, contributing to broader access in Canada>>>.
Importance 75 Sentiment 70
per
Eileen O Reilly
Eileen O Reilly, a pancreatic cancer specialist at Memorial Sloan Kettering Cancer Center, was the lead author of a paper detailing daraxonrasib's results, providing expert insight into the drug's efficacy and patient adherence.
Importance 60 Sentiment 70
per
Manuel Hidalgo
Manuel Hidalgo, director of NYU Grossman School of Medicine's Gastrointestinal Cancer Center, emphasized the drug's practice-changing potential and the need for further research into its efficacy across different genetic mutations.
Importance 60 Sentiment 70
govactor
Canada — Health Canada
Canada — Health Canada>>> has not yet received an application to license daraxonrasib in Canada>>>. Its role is to regulate and approve new drugs for use in the country, impacting the timeline for Canadian patient access.
Importance 60 Sentiment 50
per
Rachna Shah
Rachna Shah, from the University of Arizona Cancer Center, expressed strong emotional support for the drug's potential, highlighting its meaningful benefit to patients.
Importance 50 Sentiment 60
per
Andrew Coveler
Andrew Coveler, from the Fred Hutchinson Cancer Center, affirmed that daraxonrasib will change pancreatic cancer treatment due to its drastically different mechanism.
Importance 50 Sentiment 60
+ 14 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.